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Abstract
Background: Coronary heart disease (CHD) mortality rates have been decreasing in Iceland since the 1980s. We examined
how much of the decrease between 1981 and 2006 could be attributed to medical and surgical treatments and how much
to changes in cardiovascular risk factors.
Methodology: The previously validated IMPACT CHD mortality model was applied to the Icelandic population. The data
sources were official statistics, national quality registers, published trials and meta-analyses, clinical audits and a series of
national population surveys.
Principal Findings: Between 1981 and 2006, CHD mortality rates in Iceland decreased by 80% in men and women aged 25
to 74 years, which resulted in 295 fewer deaths in 2006 than if the 1981 rates had persisted. Incidence of myocardial
infarction (MI) decreased by 66% and resulted in some 500 fewer incident MI cases per year, which is a major determinant of
possible deaths from MI. Based on the IMPACT model approximately 73% (lower and upper bound estimates: 54%–93%) of
the mortality decrease was attributable to risk factor reductions: cholesterol 32%; smoking 22%; systolic blood pressure
22%, and physical inactivity 5% with adverse trends for diabetes (25%), and obesity (24%). Approximately 25% (lower and
upper bound estimates: 8%–40%) of the mortality decrease was attributable to treatments in individuals: secondary
prevention 8%; heart failure treatments 6%; acute coronary syndrome treatments 5%; revascularisation 3%; hypertension
treatments 2%, and statins 0.5%.
Conclusions: Almost three quarters of the large CHD mortality decrease in Iceland between 1981 and 2006 was attributable
to reductions in major cardiovascular risk factors in the population. These findings emphasize the value of a comprehensive
prevention strategy that promotes tobacco control and a healthier diet to reduce incidence of MI and highlights the
potential importance of effective, evidence based medical treatments.
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Introduction
Life expectancy in Iceland is increasing and the gap between
men and women is narrowing. Compared with other nations, life
expectancy for Icelandic men is the highest in Europe at 79.6
years, and for Icelandic women comes seventh at 83.0 years [1].
The successful lowering of premature deaths before the age of 75
can be largely attributed to the decline in coronary heart disease
(CHD) death rates, which between 1981 and 2006 fell 80% in men
and women. This means that 295 fewer cardiac deaths (ICD10:
I20–I25) occurred than would have been expected for this
population if 1981 mortality rates had persisted [1].
These 295 fewer deaths thus represented 69% of the 426
fewer deaths resulting from the large decrease in total mortality
rates in Iceland between 1981 and 2006. In the age group 25–
74 years, this involved a 47% fall in men and a 30% fall for
women.
The Icelandic Heart Association (IHA) was established in 1966,
and in 1967 it began the Reykjavik Study, a prospective
population based cardiovascular survey [2] An earlier report from
the Reykjavik Study described the increase in mortality in
Icelandic men until the late 1970s and then the decrease during
1981 – 1986, along with corresponding changes in risk factor levels
and food consumption.[3]
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Since 1996, Capewell and colleagues have developed and
refined a CHD mortality model called IMPACT. This model has
been used to explore the recent declines in CHD mortality in
diverse populations, and to comprehensively assess the potential
contribution of medical treatments and risk factor changes. The
model was validated against the actual mortality falls observed in
England, Scotland, Ireland New Zealand, Finland, Sweden, and
the USA. [4,5,6,7,8,9,10] It was also used to assess substantial
increases recently seen in China.[11] The model was also able to
calculate the life-years gained by different interventions [12,13],
and to perform cost-effectiveness analyses.[14]
The IMPACT model was subsequently used to address policy
questions, estimating the additional deaths which could potentially
be prevented, either by increasing the uptake of appropriate
treatments in eligible patients,[15] or alternatively, by further
modest reductions in specific risk factors.[16,17] Results using the
IMPACT model were generally consistent with other studies using
diverse methodologies in different countries.[18,19,20,21]
In this paper, we applied the IMPACT model to Icelandic data
to explain the very large decline in coronary heart disease
mortality in Iceland between 1981 and 2006 for men and women
aged 25–74 years.
Methods
The IMPACT CHD mortality model
IMPACT was used to combine and analyse data on the
Icelandic population (total 304,334 in 2006) aged 25–74 years
(177,364 in 2006), stratified by age and sex. The Model includes
comprehensive coverage of all standard evidence-based medical
and surgical treatments used for coronary heart disease,
quantifying the use and effectiveness of specific treatments. The
model also estimates the mortality effects of changes in the major
population risk factors for coronary heart disease: smoking, total
cholesterol, systolic blood pressure, body mass index, diabetes and
physical activity.
We therefore incorporated data for men and women aged 25 to
74 years in Iceland detailing:
a) CHD patient numbers (categorised by disease sub-group):
Hospital discharge Records on myocardial infarction (MI),
percutaneous coronary intervention (PCI) and coronary artery
bypass grafting (CABG) for the population of Iceland available
from 1981 to 2006 and maintained by the Icelandic Heart
Association.
b) use of specific medical and surgical treatments from
Landspitali University Hospital (LSH). It is the only hospital in
Iceland providing PCI and CABC procedures and almost none
are performed abroad. The hospital is also the primary treating
facility for 80% of all myocardial infarctions.
c) effectiveness of specific cardiological treatments,
d) population trends in major cardiovascular risk factors
(smoking, total cholesterol, systolic blood pressure, obesity,
diabetes and physical activity), based on population studies by
the Icelandic Heart Association.
and
e) effectiveness of specific risk factor reductions based on
published meta-analyses.
Data from other sources were used only in rare instances. Data
sources are summarised in Table 1, and are detailed in the
Supplementary Appendix S1.
Deaths prevented or postponed in 2006
The number of CHD deaths expected in 2006 if the mortality
rates in 1981 had persisted was calculated by indirect age
standardization by sex and 10-year age groups from age 25–74,
using 1981 as the base year. The CHD deaths actually observed in
2006 were then subtracted to give the difference in CHD deaths
between 1981 and 2006 (Table 2).
Mortality reductions attributable to treatments
The IMPACT Model aims to be comprehensive, and includes
all standard medical and surgical treatments provided in 1981 and
2006. These interventions are listed in Table 3 and included all the
treatments considered in earlier versions of the IMPACT Model,
plus primary angioplasty and stenting for myocardial infarction,
statins for primary prevention, platelet IIB/IIIA inhibitors and
clopidogrel for unstable angina, and spironolactone and beta-
blockers for heart.
To avoid double counting, potential overlaps between different
groups of patients were identified and adjustments were made
using previously tested methods.[6]
The potential effect of multiple treatments in an individual
patient was estimated using the Mant and Hicks cumulative
relative benefit approach [22]:
Relative Benefit = 12[(12Treatment A)6 (12Treatment B)6
NNN6 (12Treatment N).
A number of effective therapies were already in limited use in
1981. These included CABG surgery, cardiopulmonary resuscita-
tion, beta-blockers for acute myocardial infarction, and therapy for
moderate and severe hypertension (defined as a diastolic blood
pressure .105 mmHg). Precise patient data for some of these
interventions, such as CABG, and eligible hypertensives, were
obtained from the data sources detailed above. Others were
estimated after consultation with cardiologists in practice in 1981.
Mortality reductions attributable to changes in risk
factors
Two approaches were used to calculate the numbers of deaths
prevented or postponed as a result of changes in risk factors.
a) We used a regression approach for systolic blood
pressure, cholesterol, and body mass index (BMI). The number
of deaths prevented or postponed as a result of the change in the
value for each of these risk factors (Table 4) was estimated as the
product of three variables: the number of CHD deaths observed in
2006 if rates from 1981 persisted (the base year), the subsequent
reduction in that risk factor and the regression coefficient
quantifying the change in mortality from coronary heart disease
per unit of absolute change in the risk factor (Supplementary
Appendix S1). For example, in 2006 there were 12 CHD deaths
among 9369 women aged 65–74; the expected number of deaths
would have been 69 if rates from 1981 persisted. Between 1981
and 2006 the mean systolic blood pressure in this group decreased
by 7.9 mmHg. The largest meta-analysis showed an estimated
age- and sex-specific reduction in mortality of 50% for every
20 mmHg reduction in systolic blood pressure, generating a
logarithmic coefficient of –0.032.[23] The number of deaths
prevented or postponed as a result of the change observed in
Iceland was then estimated as:[6]
Number of deaths prevented = (12e(coefficient x change) ) x
expected deaths in 2006
= (12e (20.03267.9) )669= 15.
b) A population-attributable risk fraction approach was
used to determine the impact of changing prevalence of smoking,
diabetes and physical inactivity. The population-attributable risk
fraction was calculated conventionally as (P x (RR-1))/(1+P x (RR-
1)) where P is the prevalence of the risk and RR is the relative risk
for CHD mortality associated with that risk factor. The number of
deaths prevented or postponed was then estimated as the number
Heart Disease in Iceland
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Table 2. Population numbers and CHD deaths in Iceland 1981 and 2006 with estimated fall in CHD deaths in 2006 if 1981 rates
persisted.
CHD deaths
CHD deaths if 1981 rate
persisted
Men 1981 2006 1981 2006 2006 Fall in deaths
25–34 18638 23135 1 0 1 1
35–44 12482 22419 6 2 11 9
45–54 11012 21594 19 7 37 30
55–64 9149 15097 59 18 97 79
65–74 6154 8715 101 35 143 108
TOTAL 57,435 90,960 186 62 290 228
Women 1981 2006 1981 2006 2006 Fall in deaths
25–34 17449 21650 0 0 0 0
35–44 12035 21084 0 0 0 0
45–54 10945 19873 1 2 2 0
55–64 9325 14428 9 3 14 11
65–74 6962 9369 51 12 69 57
TOTAL 58,697 88,410 61 17 84 67
Total 247 79 374 295
doi:10.1371/journal.pone.0013957.t002
Table 1. Main Data Sources for the Parameters Used in the Iceland IMPACT Model.
Data 1981 2006
Population statistics
Population, deaths, CHD mortality Statistics Iceland Statistics Iceland
Surgical and medical treatments
Number of patients admitted yearly: MI, AP,
HF, and treated CABG, PCI
Icelandic Heart Association, Landspitali - National Hospital Icelandic Heart Association,
Landspitali - National Hospital
Cardiopulmonary resuscitation in the
community
Assume zero Landspitali - National Hospital
Hospital Resuscitation Assume zero Landspitali - National Hospital
Thrombolysis Assume zero Landspitali - National Hospital
Aspirin Assume zero Landspitali - National Hospital
Beta blockers Assume zero Landspitali - National Hospital
Warfarin Assume zero Landspitali - National Hospital
Heparin Assume zero Landspitali - National Hospital
ACE inhibitors Assume zero Landspitali - National Hospital
Statins Assume zero Landspitali - National Hospital
REFINE Reykjavik Study
(data from 2005–2007)
Risk factors
Smoking Reykjavik Study – Stage III, IV, MONICA Survey
(data from 1979 – 1983)
REFINE Reykjavik Study
(data from 2005–2007)
Hypertension prevalence
Systolic blood pressure
Cholesterol
Physical activity
Obesity (BMI)
Diabetes
doi:10.1371/journal.pone.0013957.t001
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of expected deaths from coronary heart disease in 2006 if 1981
rates persisted (the base year) multiplied by the difference between
the population-attributable risk fraction in 1981 and that in 2006.
For example, the prevalence of diabetes in men aged 65–74 years
increased from 8.7% in 1981 to 14.6% in 2006. The expected
number of deaths would have been 143 in 2006 if rates from 1981
persisted. Given a relative risk of 1.93[9], the population-
attributable risk fraction increased from 0.075 to 0.119. Additional
deaths in 2006 attributable to an increased prevalence of diabetes
were therefore calculated as follows:[6]
Additional deaths in 2006= (143)6 (0.119 – 0.075) = 6.4.
Because all the regression coefficients and relative risks for each
risk factor were independent, being taken from multivariate
analyses, we assumed that there was no further synergy between
the major risk factors or between treatment and risk factor sections
of the model.
The numbers of deaths prevented or postponed as a result of
risk factor changes were systematically quantified for each specific
age group in men and women to account for potential differences
in effect. It was assumed that lag times between the change in the
risk factor rate and event rate change would be relatively
unimportant over a period of 25 years. [6,24,25]
Sensitivity Analyses
Because of the uncertainties surrounding many of the values,
multi-way sensitivity analyses were performed using Brigg’s
analysis of extremes method.[26]. Minimum and maximum
mortality reductions were generated for therapeutic effectiveness,
using 95% confidence intervals for relative risk values obtained
from the most recent meta-analyses. The minimum and maximum
plausible values for the remaining key parameters reflected the
quality of the available data. Current default values in the
IMPACT Model are: eligible patient numbers +10%, treatment
uptake +20%, and compliance +25%. Corresponding sensitivity
analyses were constructed for risk factors, the key parameters
being change in risk factor levels, the CHD death numbers in
1981, the base year and the b coefficient or relative risk.
Results
Mortality trends 1981–2006
Between 1981 and 2006 in the age range 25–74, the
standardized mortality rate for coronary heart disease (ICD-9
410-414) decreased 79% from 324 to 68 for every 100,000 men
and decreased 82% in women, from 431 to 88 per 100,000 (direct
Table 3. Estimated deaths prevented or postponed by medical or surgical treatments in Iceland 2006.
TREATMENTS
Patients
Eligible
Best estimate
(no. of deaths) Min Max
Best estimate
(% of total)
Min
(%) Max (%)
Acute MI 247 9 1 10 3.2 0.2 3.3
Unstable Angina 358 7 3 9 2.3 1.2 2.9
29 Prev Post AMI 1649 14 6 29 4.9 2.1 9.7
29 Prev Post CABG/Ax 1147 10 4 19 3.3 1.3 6.6
Chronic Angina 3990 8 5 18 2.9 1.8 6.0
Hospital Heart Failure 81 5 1 3 1.5 0.3 1.0
Community H Failure 956 12 5 14 4.0 1.6 4.7
Hypertension Treatment 37913 7 1 14 2.2 0.2 4.6
TOTAL Statins, Gem & Niacin 19 prevention 92283 1 1 3 0.5 0.2 1.0
Total Treatment 73 23 117 24.7 7.9 39.8
doi:10.1371/journal.pone.0013957.t003
Table 4. Deaths from coronary heart disease prevented or postponed as a result of changes in population risk factors in Iceland
1981 – 2006.
Risk factor levels Risk factor change RR or coef DPP Best Min;Max Fall (%)
Min;Max
(%)
1981 2006 Absolute
Relative
(%)
Smoking (PARF) 46.5% 22.6% 23.8 251.3 2.52 65 52;80 22.0 17.6;26.4
Systolic BP
(regression)
126.3 121.2 5.1 24.0 20.03 65 46;90 22.0 15.5;31.0
Cholesterol (regression) 6.01 5.14 0.87 214.5 20.68 95 64;115 31.6 21.7;39.5
Physical Inactivity (PARF) 76.8% 53.8% 23.0 230.0 1.27 15 13;20 5.4 4.3;6.5
BMI (regression) 25.0 27.0 22.0 7.8 0.03 215 27; 220 24.4 22.5; 26.9
Diabetes (PARF) 1.7% 3.6% 21.9 107.4 1.93 215 29; 220 24.6 23.2, 26.3
Total Risk Factors 210 158;265 72.6 53.5;90.2
doi:10.1371/journal.pone.0013957.t004
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method , Icelandic census 1981) (3,4). This fall resulted in 295
fewer deaths observed in 2006 (Table 2).
The mortality fall estimated by the IMPACT model showed a
reasonably good fit in specific age and sex groups (Figure 1).
Mortality reduction attributable to medical and surgical
treatments
The model suggested that treatments together accounted for
approximately 73 fewer deaths in 2006 (minimum estimate 23,
maximum 117). Thus, approximately one quarter (25%) of the 295
fewer deaths was attributable to treatments in individuals:
including some 8% to secondary prevention, 6% to heart failure
treatments, 6% to initial treatments of acute coronary syndrome,
2% to hypertension treatments, 0.5% to statins for primary
prevention, and revascularisation accounted for approximately 3%
(principally angioplasty in patients with AMI or unstable angina.)
(Table 3).
Mortality reduction attributable to risk factor changes
Risk factor changes together accounted for approximately 215
fewer deaths in 2006 (minimum estimate 159, maximum estimate 275).
(Table 4).
The largest contribution came from reductions in cholesterol (95
fewer deaths), systolic blood pressure (65) and smoking (also 65).
Almost three quarters of the mortality decrease (73%) was thus
attributable to population risk factor reductions (principally
cholesterol, 32%; smoking, 22% and systolic blood pressure,
22%, with 5% from increase in physical activity).
Adverse trends were seen for diabetes prevalence (increasing
from 1.7% to 3.6%) and obesity (mean BMI rising from 25.0 to
27.0). These rises together generated approximately 30 additional
deaths (minimum estimate 16, maximum estimate 40).
Sensitivity analyses
Treatments together accounted for approximately 25% of the
mortality fall (minimum estimate 8%, maximum 40%). Risk factors
contributed the remaining 73% (minimum 54%, maximum 93%)
with approximately 2.7% of the fall not being explained by the
model. The mortality reductions attributable to specific treatments
were thus consistently smaller than those achieved by reductions in
the major risk factors (Figure 2).
Discussion
Between 1981 and 2006, coronary heart disease mortality rates
in Iceland decreased by 80% in men and women aged 25 to 74
years. This is one of the largest falls recorded in Western
populations, averaging 3.2% per year over two and a half decades.
It compares well with Finland (4.2% per annum), Sweden (3.3%)
[10], the UK (2.8%) [27], and the USA (2.5%) [9].
This huge mortality fall resulted in 295 fewer deaths in 2006 in
Iceland. Approximately one quarter of the mortality decrease
(25%) was attributable to treatments in individuals. Useful
contributions came from secondary prevention, heart failure
treatments, and initial treatments of acute coronary syndrome
much as in Sweden (10) and Finland (7). The contribution from
revascularizations was modest, reflecting a relatively small number
of eligible patients and limited mortality benefits in stable
angina[25]. However, the improvement in quality of life is
important and well recognized [28].
Risk factor changes together accounted for approximately 210
fewer deaths in 2006 (minimum estimate 158, maximum estimate 265).
Thus over 70% of the large mortality decrease was attributable
to population risk factor reductions. The main contributions
came from secular falls in cholesterol, (32%); systolic blood
pressure, (22%) and smoking, (22%). A further 5% came from
increases in physical activity, in line with trends in Scandinavia
(7, 10).
This mortality fall in turn reflected a large fall of some 500 fewer
incident MI cases in 2006 (than if 1981 rates persisted): The total
MI incidence rate declined by 66% for men and women between
1981 and 2006 (Figure 3). Any further reduction in CHD deaths is
mainly going to be obtained through further reduction in the
incidence of MI. Therefore, in spite of the dramatic falls in major
cardiovascular risk factors, there remains an additional potential
Figure 1. Model fit comparing observed and estimated mortality falls in each age group. (diamonds = best estimate, bars maximum and
minimum estimate).
doi:10.1371/journal.pone.0013957.g001
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for further improvement. Having used the IMPACT Model to
successfully quantify the Icelandic population in 2006, we should
now explore the further reduction in mortality that might be
achieved. For instance if mean total cholesterol levels were
decreased to 5.0 or even 4.5 mmol/l, systolic blood pressure levels
to 115 mmHg and smoking prevalence to just 10% of adults.
[29]
As in Finland, Sweden China and elsewhere, cholesterol was the
most powerful risk factor; this remains true whether considered as
sub-fractions or in total. In middle aged adults, a 1 mmol/l
reduction will reduce CHD mortality rates by approximately one
third[30]. Cholesterol levels are powerfully influenced by diet,
particularly the relative intake of (‘‘good’’) polyunsaturated fats
from vegetable oils, nuts and fish versus (‘‘bad’’) saturated fats from
Figure 2. The proportional contributions of specific risk factor treatments and risk factor changes to the overall decrease in CHD
mortality in Iceland between 1981 and 2002. The bars show the observed deaths in each age group, with diamonds being the best model
estimate, and vertical lines the extreme minimum and maximum estimates in the sensitivity analysis.
doi:10.1371/journal.pone.0013957.g002
Figure 3. CHD mortality rates and MI incidence rates in Iceland between 1981 and 2006 for men and women of age 25–74. The rates
have been declining along the superimposed trend lines.
doi:10.1371/journal.pone.0013957.g003
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meat and dairy products) and (‘‘very bad’’) transfats from
hydrogenated fatty acids concealed in junk food, processed food,
cakes and cookies.[31]
The large (0.87 mmol/l) fall in cholesterol between 1981 and
2006 reflects major changes in the Icelandic diet following the
issue of Dietary Goals for Icelanders, published by the National
Nutrition Council in the fall of 1986 and subsequent approval of a
National Food and Nutrition Policy by both the executive and
parliamentary branch of the Icelandic government in May 1989.
The National policy is based on the dietary goals where the
reduction of saturated fat, mainly from milk and dairy products,
butter, lamb and margarine, is greatly emphasized. The food
policy and the dietary goals have greatly influenced nutrition
education and awareness in the country.
Icelandic food supply data clearly demonstrate the subsequent
changes. In the 1970s, the diet was characterized by high
consumption of whole milk and dairy products, margarine, butter,
lamb, mutton and fish. However, between 1980 and 2006 there
was a 73% drop in whole milk and dairy consumption (from
238 kg/person/year to 64 kg/person/year) and the supply of
lamb and mutton decreased by 50% (from 47 kg/person/year to
24 kg/person/year). The lamb supply has been replaced by other
meat products, mainly poultry and pork. Further, the supply of
margarines made from hydrogenated fats and used for cooking
and baking, has plummeted by 73% (from 11.7 kg/person/year to
3.2 kg/person/year), the largest drop occurring in the 1990s,
when the most significant drop in cholesterol was also seen. From
the 1990s, the consumption of total fat in percent energy (E%)
calculated from the food supply statistics has decreased from
40E% to 36E% . But more importantly, the composition of the fat
has also changed from more saturated and trans-fatty acids to cis-
unsaturated.[32] In contrast, statins played a relatively small role
in lipid lowering at the population level for middle aged Icelanders
up until 2006.[33]
Solid data on salt or sodium intake on a population level are not
available. However during this period a gradual shift occurred
from the traditional Icelandic foods dominated by salted and cured
meats and fish, to fresh and frozen foods. The contribution of these
changes to the fall in blood pressure can only be hypothesized.
Smoking prevalence fell substantially from 47% to 23% overall
of which prevalence for non-cigarette smokers fell from 14% to
under 3% in 2006. This reflects series of successful tobacco control
initiatives including a ban on advertising tobacco in 1971, ban on
smoking at workplaces in 1985, ban on selling tobacco to minors in
1996, culminating in legislation to ban smoking in public spaces in
June 2007.
However, adverse trends were seen for obesity and diabetes,
increasing mortality by 4% and 5% respectively. This mirrors
similar disappointing increases in the UK and USA. It mainly
reflects excessive intake of calories not compensated by the
amount of physical activity in daily life, (even though leisure
physical activity levels increased).[34] Future policies will therefore
need to focus on calorie restriction at individual, local and national
levels.
Strengths and limitations of this study
The best modelling studies have a number of potential
strengths. They can transparently consider and simultaneously
integrate large amounts of data from many sources. Explicit
assumptions can then be tested by sensitivity analyses [6]. Yet
modelling studies also have limitations. They represent crude
simplifications of a complex reality. In particular, they depend on
the variable extent and quality of data available on CHD risk
factor trends and treatment uptakes. However, population data
and hospital discharge registries in Iceland are particularly good
and almost 100% complete. Since Iceland has almost no private
hospitals and no private Cardiac Care Units (CCUs), the data
cover more than 99% of our hospital patients, and clearly capture
the majority of the Icelandic population. This, together with a long
tradition of high quality national population surveys and registries,
reduces the potential problem of needing to make assumptions
about dubious data.
The number of people aged 25–74 in Iceland is small (about
180000 in 2006) and CHD deaths few (79 in 2006), which is
reflected in large margins of errors. However, the drop in CHD
deaths and MI has been uniform since 1981 in this agegroup and
the estimates from the model are consistent with observed data
(Figure 1).
The model included only those adults aged 25 to 74 years old
because of very limited data in older groups. Elderly patients and
women have been consistently underrepresented in a majority of
clinical trials and surveys in cardiovascular disease[35]. This
highlights the need for further work on cardiovascular risk factors
in the elderly.
In conclusion, almost three quarters of the large coronary heart
disease mortality decrease in Iceland between 1981 and 2006 was
attributable to reductions in major cardiovascular risk factors in
the population, (mainly decreases in total serum cholesterol,
smoking and blood pressure levels). These findings emphasize the
value of a comprehensive strategy that promotes a healthier diet
and further tightens tobacco control. It also highlights the potential
importance of effective evidence based medical treatments for all
eligible patients.
Supporting Information
Appendix S1 IMPACT, a validated, comprehensive coronary
heart disease model. Supplementary appendix for the Icelandic
model.
Found at: doi:10.1371/journal.pone.0013957.s001 (0.51 MB
DOC)
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